Fellowship · Columbus, OH
Sponsored by Ohio State University Hospital
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Frontiers in immunology · 2022 · 291 citations · Ashish Manne
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma.
NPJ precision oncology · 2025 · 16 citations · Ashish Manne
Large Language Models for Adverse Drug Events: A Clinical Perspective.
Journal of clinical medicine · 2025 · 11 citations · Ashish Manne
Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Cancers · 2022 · 37 citations · Ashish Manne
Rh immune globulin immunoprophylaxis after RhD-positive red cell exposure in RhD-negative patients via transfusion: A survey of practices.
Transfusion · 2024 · 6 citations · Aaron Shmookler
Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · 7 citations · Ashish Manne
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.
Journal of experimental & clinical cancer research : CR · 2024 · 17 citations · Ashish Manne
Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review.
Frontiers in oncology · 2025 · 6 citations · Ashish Manne